Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total revenue, net		$ 42,298	$ 66,056	$ 166,308	$ 232,198
Less: Cost of goods sold		26,022	23,560	75,359	72,553
Less: Cost of goods sold - restructuring inventory		0	12,674	0	39,228
Gross margin		16,276	29,822	90,949	120,417
Operating expenses:
Selling, general and administrative		36,904	45,457	115,340	155,997
Research and development		4,540	5,105	14,884	16,428
Restructuring			711		10,743
Total operating expenses		41,444	51,273	130,224	183,168
Operating loss		(25,168)	(21,451)	(39,275)	(62,751)
Interest income, net		3,374	3,216	10,028	8,438
Other income (expense), net		265	(575)	1,954	3,092
Loss from operations before taxes		(21,529)	(18,810)	(27,293)	(51,221)
Provision for income taxes		(3,605)	(501)	(6,272)	(2,110)
Net loss		$ (25,134)	$ (19,311)	$ (33,565)	$ (53,331)
Loss per share:
Basic	[1]	$ (0.06)	$ (0.05)	$ (0.08)	$ (0.13)
Diluted	[1]	$ (0.06)	$ (0.05)	$ (0.08)	$ (0.13)
Weighted average shares:
Basic		411,150	408,417	410,786	407,489
Diluted		411,150	408,417	410,786	407,489
Product Revenue, Net
Total revenue, net		$ 41,852	$ 64,903	$ 144,522	$ 214,744
Licensing and Royalty Revenue
Total revenue, net		$ 446	$ 1,153	$ 21,786	$ 17,454

[1] Excluding the licensing revenue change in estimates and Medicaid change in estimate, both discussed in Note 7 – Revenue Recognition, net loss per share, basic and diluted, for the three months ended September 30, 2023 would have been $(0.06) and net loss per share for the nine months ended September 30, 2024 and 2023 would have been $(0.09) and $(0.19), respectively.